Live biotherapeutics in the clinic: Regulatory pathways, market dynamics, and future trends.
Level 5 - mechanism / opinion, no new human data
Narrative review and industry landscape analysis without primary clinical data.
PubMed 41714086 · doi:10.1016/bs.pmbts.2026.01.029
What was done
The authors reviewed the clinical development, regulatory frameworks (US FDA and EMA), manufacturing challenges, and commercial trajectories of Live Biotherapeutic Products (LBPs), including natural, consortium-based, and recombinant strains.
What was found
The approvals of Rebyota and Vowst for recurrent Clostridioides difficile infection marked the establishment of LBPs as an approved therapeutic class. The global LBP market is currently estimated in the tens to low hundreds of millions of USD and is projected to grow at compound annual rates of approximately 13% to 25%, reaching USD 400 million to 2.6 billion by 2030–2034. Emerging recombinant LBPs are expanding therapeutic delivery, though clinical translation faces barriers in manufacturing complexity, potency assays, donor sourcing, biosafety for GMOs, and reimbursement.
Why it matters
It summarizes the translational, regulatory, and economic state of microbiome therapeutics as the field expands beyond niche gastrointestinal indications.
Limits
This is a narrative review with no primary clinical trial data, systematic search criteria, or quantitative synthesis. Market figures represent economic projections rather than measured outcomes.
Cited by
- contradicts No probiotic preparation has been approved as a medical drug intervention by the FDA or the European Medicines Agency.